var data={"title":"Daclizumab (Withdrawn from market): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Daclizumab (Withdrawn from market): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5971?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=daclizumab-withdrawn-from-market-drug-information\" class=\"drug drug_general\">see &quot;Daclizumab (Withdrawn from market): Drug information&quot;</a> and <a href=\"topic.htm?path=daclizumab-withdrawn-from-market-patient-drug-information\" class=\"drug drug_patient\">see &quot;Daclizumab (Withdrawn from market): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51164771\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Zinbryta Market Withdrawal</span>\n      <span class=\"collapsible-date\">3/2/2018</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Biogen and AbbVie have announced the voluntary worldwide withdrawal of Zinbryta (daclizumab) for the treatment of adult patients with relapsing forms of multiple sclerosis. The companies believe that characterizing the complex and evolving benefit/risk profile of Zinbryta will not be possible going forward given the limited number of patients being treated. Patients currently treated with Zinbryta should contact their health care provider if they have any questions or concerns. The drug will be available for patients as needed until April 30, 2018. It is important that patients continue to have monthly liver function tests for 6 months <i>after</i> the last dose.</p>\n        <p style=\"text-indent:0em;\">More information may be found at http://media.biogen.com/press-release/autoimmune-diseases/biogen%C2%A0and-abbvie-announce%C2%A0-voluntary%C2%A0worldwide-withdrawal-marketi or https://www.fda.gov/Drugs/DrugSafety/ucm600999.htm?utm_campaign=FDA%20working%20with%20manufacturers%20to%20withdraw%20Zinbryta%20from%20the%20market%20in&amp;utm_medium=email&amp;utm_source=Eloqua or http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2018/66214a-eng.php.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708688\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hepatotoxicity including autoimmune hepatitis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Daclizumab can cause severe liver injury, including autoimmune hepatitis and liver failure. Fatal cases have occurred. Liver injury, including autoimmune hepatitis and acute liver failure, can occur at any time during treatment with daclizumab, and with cases reported up to 5 months after the last dose of daclizumab.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Daclizumab is contraindicated in patients with preexisting hepatic disease or hepatic impairment. Prior to starting daclizumab, obtain serum transaminases (ALT and AST) and bilirubin levels.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Test transaminase levels and total bilirubin monthly and assess before the next dose of daclizumab. Follow transaminase levels and total bilirubin monthly for 6 months after the last dose of daclizumab. In case of elevation in transaminases or total bilirubin, treatment interruption or discontinuation may be required.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other immune-mediated disorders:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">In addition to autoimmune hepatitis, a variety of immune-mediated disorders including skin reactions, lymphadenopathy, noninfectious colitis, and other serious conditions can occur in patients treated with daclizumab. Overall, serious immune-mediated disorders were observed in 5% of patients treated with daclizumab. If a patient develops a serious immune-mediated disorder, consider stopping daclizumab and refer the patient to a specialist to ensure comprehensive diagnostic evaluation and appropriate treatment.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Systemic corticosteroids:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Some patients required systemic corticosteroids or other immunosuppressant treatment for autoimmune hepatitis or other immune-mediated disorders and continued this treatment after the last dose of daclizumab.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">REMS Program:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Because of the risks of hepatic injury, including autoimmune hepatitis, and other immune-mediated disorders, daclizumab is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the ZINBRYTA REMS Program.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46915411\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Zinbryta</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49410938\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Zinbryta</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046839\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Immunosuppressant Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046833\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=daclizumab-withdrawn-from-market-drug-information\" class=\"drug drug_general\">see &quot;Daclizumab (Withdrawn from market): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Screen patients for hepatitis B and C prior to treatment initiation. Avoid initiating treatment in patients with severe active infection (including tuberculosis).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Multiple sclerosis, relapsing</b>: Adolescents &ge;17 years: SubQ: 150 mg once monthly. Administer a missed dose as soon as possible, but no more than 2 weeks late; after 2 weeks, skip the missed dose and administer the next dose on schedule. Administer only 1 dose at a time.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Multiple sclerosis, relapsing</b>: SubQ: 150 mg once monthly (Gold 2013, Kappos 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Missed dose: Administer a missed dose as soon as possible, but no more than 2 weeks late; after 2 weeks, skip the missed dose and administer the next dose on schedule. Administer only 1 dose at a time.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Adolescents &ge;17 years and Adults: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment: </b>Adolescents &ge;17 years and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preexisting hepatic disease or impairment, including ALT or AST &ge;2 times ULN or history of autoimmune hepatitis (or other autoimmune condition involving the liver): Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatotoxicity during treatment: ALT or AST &gt;5 times ULN or total bilirubin &gt;2 times ULN or ALT or AST &ge;3 to &lt;5 times ULN AND total bilirubin &gt;1.5 to &lt;2 times ULN: Interrupt treatment and investigate for other etiologies of abnormal lab value. If no other etiologies are identified, discontinue daclizumab. If other etiologies are identified, evaluate overall risk versus benefit of daclizumab relative to the patient and consider if appropriate to resume daclizumab treatment when BOTH AST or ALT &lt;2 times ULN AND total bilirubin &le;ULN. In clinical trials, treatment was permanently discontinued if liver function test abnormalities resulted in a treatment suspension of at least 8 consecutive weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Suspected autoimmune hepatitis: Promptly discontinue daclizumab; may require systemic corticosteroids and other immunosuppressant therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for toxicity: </b>Adolescents &ge;17 years:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Anaphylaxis or other allergic reaction: Discontinue treatment; do not re-initiate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Depression (severe) or suicidal ideation: Consider discontinuing treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic toxicity: Serious diffuse or inflammatory rashes: Discontinuation may be appropriate; consider referral to a dermatologist for evaluation prior to the next dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immune-mediated disorders, serious: Consider discontinuing daclizumab and refer to a specialist; may require systemic corticosteroids or other immunosuppressant treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection (serious): Consider withholding daclizumab until infection resolves.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46915412\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution Prefilled Syringe, Subcutaneous [preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Zinbryta: 150 mg/mL (1 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51237083\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;\">As of March 2, 2018, Biogen and AbbVie have announced the voluntary worldwide withdrawal of Zinbryta (daclizumab) for the treatment of adult patients with relapsing forms of multiple sclerosis. The drug will be available in the United States and Canada for patients as needed until April 30, 2018.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">More information may be found at http://media.biogen.com/press-release/autoimmune-diseases/biogen%C2%A0and-abbvie-announce%C2%A0-voluntary%C2%A0worldwide-withdrawal-marketi or https://www.fda.gov/Drugs/DrugSafety/ucm600999.htm?utm_campaign=FDA%20working%20with%20manufacturers%20to%20withdraw%20Zinbryta%20from%20the%20market%20in&amp;utm_medium=email&amp;utm_source=Eloqua or http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2018/66214a-eng.php.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49639351\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761029s001lbl.pdf#page=24&amp;token=TzQ4wPw76dQovXs1+F3IqBQJoibJVdDtl/06yM1OROPrm8/17fPXzper/SMtd/D8XqCnHIaxejJDyi15fp9E4xCGm6A0MvYa9Kwzq4K7SV350m+0VG6p0Pg4NyCY+CNP&amp;TOPIC_ID=13201\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761029s001lbl.pdf#page=24</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046843\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">For subcutaneous administration only. Allow to warm to room temperature 30 minutes prior to injection. Administer subcutaneously into the thigh, abdomen, or back of the upper arm. Patients may be trained on proper technique for self-administration. Use each prefilled syringe one time and then place in a sharps container for disposal according to community guidelines.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46815261\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Do not expose to temperatures above 30&deg;C (86&deg;F). Do not freeze (discard if frozen). Keep in the original carton to protect from light.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">If refrigeration is unavailable, may be stored protected from light for up to 30 days at up to 30&deg;C (86&deg;F). Do not place back into the refrigerator after allowing it to warm to room temperature. Discard after 30 days without refrigeration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046842\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of relapsing forms of multiple sclerosis (MS) (FDA approved in ages &ge;17 years and adults); <b>Note:</b> Daclizumab should generally be reserved for patients who have had an inadequate response to 2 or more medications indicated for the treatment of MS.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49190693\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-4em;margin-left:6em;\">Zinbryta may be confused with Zinplava.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46720595\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Depression, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Acne vulgaris, allergic skin reaction, dermatitis, desquamation, eczema, erythema, folliculitis, pruritus, psoriasis, skin photosensitivity, skin rash, skin rash (toxic), xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, decreased absolute lymphocyte count, lymphadenitis, lymphadenopathy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Abnormal hepatic function tests, hepatic injury, increased liver enzymes, increased serum ALT, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction (including anaphylaxis, angioedema, and urticaria)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Autoimmune disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Cytomegalovirus disease, infection, influenza, viral infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchitis, laryngitis, nasopharyngitis, oropharyngeal pain, pharyngitis, pneumonia, respiratory tract infection, rhinitis, tonsillitis, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Autoimmune hepatitis, colitis (serious; noninfectious), increased serum alkaline phosphatase (&lt;2 x ULN), increased serum bilirubin (&ge;2 x ULN), increased serum transaminases (&ge;3 x ULN), malignant neoplasm of breast (more common in women), suicidal ideation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156302\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to daclizumab or any component of the formulation; preexisting hepatic disease or hepatic impairment, including ALT or AST at least 2 times the ULN; history of autoimmune hepatitis or other autoimmune condition involving the liver.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46815004\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: <b>[US Boxed Warning]: Daclizumab may cause severe hepatic injury, including hepatic failure and autoimmune hepatitis; fatal cases have occurred. Hepatotoxicity, including autoimmune hepatitis, may occur at any time during daclizumab treatment; cases have been reported up to 5</b><b> months after the last dose. Daclizumab is contraindicated in patients with preexisting hepatic disease or hepatic impairment. Obtain serum transaminases (ALT and AST) and total bilirubin levels prior to treatment initiation, monthly before each dose, and monthly for 6 months after the last daclizumab dose. If transaminases or total bilirubin are elevated, treatment interruption or discontinuation may be required. Some patients required systemic corticosteroids or other immunosuppressant treatment for autoimmune hepatitis and continued this treatment after the last daclizumab dose.</b> ALT or AST elevations (including rare elevations &gt;20 times ULN) and bilirubin elevations have occurred during treatment and up to 4 months following the last dose. Monitor for clinical signs/symptoms of hepatic dysfunction (unexplained nausea, vomiting, abdominal pain, anorexia, fatigue, jaundice, and/or dark urine); if reported, promptly obtain serum transaminases and total bilirubin; may require treatment interruption or discontinuation. Prolonged transaminase elevations should be evaluated for alternate causes, including infection. If autoimmune hepatitis is suspected, promptly discontinue daclizumab; may require systemic corticosteroids and other immunosuppressant therapy. Long-term immunosuppression may be necessary. Other medications (including OTC medications, herbals, and dietary supplements) associated with hepatotoxicity should be used with caution in combination with daclizumab.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Anaphylaxis, angioedema, and urticaria may occur after the first dose or at any time during treatment. If anaphylaxis or other allergic reaction occurs, discontinue daclizumab and do not re-initiate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immune-mediated disorders: <b>[US Boxed Warning]: In addition to autoimmune hepatitis, other immune-mediated disorders such as skin reactions, lymphadenopathy, noninfectious colitis, and other serious conditions may occur with daclizumab. Serious immune-mediated conditions were observed in 5% of patients treated with daclizumab. If a serious immune-mediated disorder develops, consider stopping daclizumab and refer to a specialist for a comprehensive diagnostic evaluation and appropriate management. Some patients required systemic corticosteroids or other immunosuppressant treatment for immune-mediated disorders and continued this treatment after the last daclizumab dose.</b> Concurrent or sequential immune-mediated disorders have been reported in some cases. Immune-mediated disorders have resulted in invasive diagnostic procedures, hospitalization, and/or prolonged systemic corticosteroids or other immunosuppressant therapy; some events had not resolved following daclizumab discontinuation and follow-up. Immune-mediated disorders have involved a single organ or systemic multi-organ inflammatory reactions. Monitor closely for immune-mediated disorders. Suspected immune-mediated disorders should be adequately evaluated to confirm etiology or to exclude other causes. Some immune-mediated disorders have required several months for resolution after the last dose and some had not resolved even several months after discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Colitis: Immune-mediated colitis, including colitis, ulcerative colitis, Crohn disease, microscopic colitis, inflammatory bowel disease, proctitis, and proctocolitis, has occurred. If symptoms of colitis (abdominal pain, fever, prolonged diarrhea) occur, consider discontinuing therapy and referring to a gastroenterologist.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Dermatologic toxicity: Immune-mediated skin reactions, including rash, dermatitis, eczema, psoriatic conditions, and drug eruptions have occurred with daclizumab; erythema multiforme, erythema nodosum, and exfoliative rash have also been reported. Skin reactions may occur at any time during therapy. Photosensitivity has also been reported. Daclizumab may exacerbate eczema or psoriasis in patients with a history of those conditions. Dermatologic toxicity may be managed with topical or systemic corticosteroids, or immunosuppressant therapy (eg, tacrolimus). Some skin reactions have required discontinuation. Rash typically resolved at ~3 months, although some rashes remained unresolved at the final clinical evaluation. Infectious complications due to serious cutaneous reaction has been reported, including a rare fatality. Serious diffuse or inflammatory rashes should be evaluated by a dermatologist prior to the next dose; discontinuation may be appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Hemolytic anemia: Immune-mediated hemolytic anemia has occurred; typically resolves with discontinuation of treatment, corticosteroid or other immunosuppressant treatment, and blood transfusions. If signs/symptoms of autoimmune hemolytic anemia occur, consider discontinuing treatment and referring to appropriate specialist for further evaluation and management.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Lymphadenopathy: An increased incidence of lymphadenopathy was reported in patients who received daclizumab. The onset of lymphadenopathy or lymphadenitis may occur throughout the daclizumab treatment period. Serious events related to lymphadenopathy/lymphadenitis included infections, salivary neoplasm (benign), skin reactions, thrombocytopenia, and interstitial lung changes. Most cases resolved within 3 months, either with treatment continuing or discontinued. If lymph node biopsy is considered, the patient should undergo a full diagnostic exam by a specialist.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Oral ulcers: Immune-mediated oral ulcers have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infection: Daclizumab increases the risk for infections (some serious). Upper respiratory tract infections, urinary tract infections, and viral infections were the most common infections; cytomegalovirus infections (hepatitis and pneumonia) have also occurred. In countries where tuberculosis is endemic, cases of tuberculosis occurred in patients receiving daclizumab. Evaluate patients at high risk for tuberculosis infection prior to treatment initiation. Avoid initiating daclizumab in patients with tuberculosis or other severe active infection. If serious infection develops while on therapy, consider withholding daclizumab until infection resolves. Screen for hepatitis B and C prior to treatment initiation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuropsychiatric events: Depression-related events occurred more frequently in patients receiving daclizumab than in patients who received placebo or comparator drug. Some events were serious, including suicidal ideation or attempt. Use daclizumab with caution in patients with prior or current depressive disorders. Patients or caregivers should immediately report symptoms of new or worsening depression or suicidal ideation. Consider discontinuing daclizumab if severe depression or suicidal ideation develops.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Patients with signs/symptoms of hepatic impairment may be at increased risk for hepatotoxicity. Use is contraindicated in patients with preexisting hepatic disease, hepatic impairment, or history of autoimmune hepatitis (or other autoimmune condition involving the liver).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002, Lucente 2000, Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986, CDC 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunizations: Immunization with live vaccines is not recommended during treatment and for up to 4 months after discontinuation. Consider necessary immunization prior to initiation of daclizumab treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunogenicity: Anti-daclizumab antibodies and neutralizing antibodies may develop, usually during the first year of treatment, with the frequency declining with continued treatment. Anti-daclizumab antibodies were transient in some patients and persistent in others.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; REMS program: <b>[US Boxed Warning]: Due to the risks of hepatotoxicity (including autoimmune hepatitis) and other immune-mediated disorders, daclizumab is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the ZINBRYTA REMS Program.</b> Prescribers and pharmacies must be certified with the program and patients must be enrolled in the program and comply with ongoing monitoring requirements. Further information is available at 1-800-456-2255.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46683162\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46683159\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13201&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Daclizumab may enhance the adverse/toxic effect of Vaccines (Live). Daclizumab may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46814997\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Daclizumab is a monoclonal antibody; monoclonal antibodies are known to cross the placenta, with increasing amounts during the second and third trimesters. Use of similar agents is not recommended for the treatment of multiple sclerosis in pregnant women (Coyle 2016, Pozzilli 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046838\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">ALT, AST, and total bilirubin (prior to treatment, then monthly during treatment [prior to the next dose] and for 6 months after the last dose). Evaluate for tuberculosis (in patients at high risk) prior to treatment. Evaluate immunization status prior to treatment. Monitor for signs/symptoms of colitis, depression, dermatologic toxicity, hepatic dysfunction, hypersensitivity, immune-mediated disorders, and infection.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46815265\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Daclizumab is a humanized monoclonal antibody which binds to the CD25 subunit of the high-affinity interleukin-2 (IL-2) receptor to prevent signaling at the high-affinity IL-2 receptor while allowing increased IL-2 availability for signaling at the intermediate-affinity IL-2 receptor (Gold 2013, Kappos 2015). Because IL-2 has a role in activating and regulating the immune system; CD25 antagonism may result in therapeutic benefit in multiple sclerosis (Gold 2013). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46815277\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Vd: SubQ: ~6.34 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Catabolized to peptides and amino acids</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: SubQ: ~90%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: SubQ: 21 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: SubQ: 5 to 7 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46961715\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Zinbryta Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg/mL (1 mL): $8,683.80</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daclizumab-withdrawn-from-market-pediatric-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daclizumab-withdrawn-from-market-pediatric-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coyle PK. Management of women with multiple sclerosis through pregnancy and after childbirth. <i>Ther Adv Neurol Disord</i>. 2016;9(3):198-210.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daclizumab-withdrawn-from-market-pediatric-drug-information/abstract-text/27134675/pubmed\" target=\"_blank\" id=\"27134675\">27134675</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gold R, Giovannoni G, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. <i>Lancet</i>. 2013;381(9884):2167-2175.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daclizumab-withdrawn-from-market-pediatric-drug-information/abstract-text/23562009/pubmed\" target=\"_blank\" id=\"23562009\">23562009</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47:313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daclizumab-withdrawn-from-market-pediatric-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kappos L, Wiendl H, Selmaj K, et al. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. <i>N Engl J Med</i>. 2015;373(15):1418-1428.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daclizumab-withdrawn-from-market-pediatric-drug-information/abstract-text/26444729/pubmed\" target=\"_blank\" id=\"26444729\">26444729</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43:172.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pozzilli C, Pugliatti M; ParadigMS Group. An overview of pregnancy-related issues in patients with multiple sclerosis. <i>Eur J Neurol</i>. 2015;22 Suppl2:34-39.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daclizumab-withdrawn-from-market-pediatric-drug-information/abstract-text/26374512/pubmed\" target=\"_blank\" id=\"26374512\">26374512</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daclizumab-withdrawn-from-market-pediatric-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zinbryta (daclizumab) [prescribing information]. Cambridge, MA: Biogen Inc; May 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13201 Version 48.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F51164771\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708688\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F46915411\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F49410938\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1046839\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1046833\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F46915412\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F51237083\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F49639351\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1046843\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F46815261\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1046842\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F49190693\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F46720595\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F156302\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F46815004\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F46683162\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F46683159\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F46814997\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1046838\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F46815265\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F46815277\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F46961715\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13201|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=daclizumab-withdrawn-from-market-drug-information\" class=\"drug drug_general\">Daclizumab (Withdrawn from market): Drug information</a></li><li><a href=\"topic.htm?path=daclizumab-withdrawn-from-market-patient-drug-information\" class=\"drug drug_patient\">Daclizumab (Withdrawn from market): Patient drug information</a></li></ul></div></div>","javascript":null}